Heart, Lung and Circulation
Volume 15, Issue 1 , Pages 3-11 , February 2006

ICD Therapy: What Have We Learned From the Clinical Trials?

References 

  1. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, et al. Task force on sudden cardiac death of the European society of cardiology. Eur Heart J. 2001;22:1374–1450
  2. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999;100:2025–2034
  3. Connolly SJ, et al. The CIDS Investigators Canadian Implantable Defibrillator Study (CIDS) a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–1302
  4. Kuck KH, et al. The CASH Investigators Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–754
  5. Domanski MJ, et al. The AVID Investigators Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Coll Cardiol. 1999;34:1090–1095
  6. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trial. Eur Heart J. 2000;21:2071–2078
  7. Brodsky MA, et al. AVID Investigators Prognostic value of baseline electrophysiology studies in patients with sustaine ventricular tachycardia: The antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. Am Heart J. 2002;144:478–484
  8. Domanski MJ, Epstein A, Hallstrom A, Saksena S, Zipes DP. Survival of antiarrhythmic or implantable cardioverter defibrillator treated patients with varying degrees of left ventricular dysfunction who survived malignant ventricular arrhythmias. J Cardiovasc Electrophysiol. 2002;13:580–583
  9. Cannon DS, Prystowsky EN. The evolution of the implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2004;27:419–431
  10. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med. 1996;335:1933–1940
  11. Moss AJ, Fadl Y, ZarebaW , Cannom DS. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease. Am J Cardiol. 2001;88:516–520
  12. Buxton AE, et al. The Multicenter Unsustained Tachycardia Trial Investigators A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341:1882–1890
  13. Buxton AE, et al. MUSTT Investigators Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the Multicenter Unsustained Tachycardia Trial. Circulation. 2002;106:2466–2472
  14. Moss AJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. Multicenter Automatic Defibrillator Implantation Trial II investigators. N Engl J Med. 2002;346:877–883
  15. Moss AJ. MADIT II and its implications. Eur Heart J. 2003;24:16–18
  16. Greenberg H, et al. MADIT-II Investigators Analysis of Mortality Events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol. 2004;43:1459–1465
  17. Kulasingam SL, et al. AVID Investigators Lower observed versus expected (based on U.S. age and gender specific rates) survival in patients treated for near-fatal ventricular arrhythmias. Pacing Clin Electrophysiol. 2004;27:230–234
  18. Mitchell LB, Pineda EA, Titus JL, Bartosch PM, Benditt DG. Sudden death in patients with implantable cardioverter defibrillators. J Am Coll Cardiol. 2002;39:1323–1328
  19. The DAVID Trial Investigators. Dual chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. JAMA 2002;288:3115–23.
  20. Bigger JT The CABG-Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary–artery bypass graft surgery. N Engl J Med. 1997;337:1569–1575
  21. Stefan H, et al. on behalf of the DINAMIT Investigators Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488
  22. Bansch D, et al. The CAT Investigators Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: The Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453–1458
  23. Strickberger SA, et al., AMIOVIRT Investigators. Amiodarone versus implantable cardioverter defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol 2003;41:1707–12.
  24. Kadish A, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–2158
  25. Bardy GH, et al., The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–37.
  26. Poole GE, et al., on behalf of the SCD-HeFT Investigators. Baseline ECG Data and Outcome in the Sudden Cardiac Death-Heart Failure Trial (SCD-HeFT ECG). Presented at American College of Cardiology Annual Scientific Sessions, New Orleans 2004–Late Breaking Trial, March 7–10, 2004. New Orleans, LA.
  27. Sweeney MO, Schoenfeld MH, Cannom DS. Rules of evidence: CMS and primary prevention of sudden cardiac death in systolic heart failure. Pacing Clin Electrophysiol. 2005;28:81–88
  28. Galizio NO, Pesce R, Valero E, Gonzalez JL, Favaloro RR, Favaloro L, et al. Which patients with congestive heart failure may benefit from biventricular pacing. Pacing Clin Electrophysiol. 2003;26:158–161
  29. Young JB, et al. Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. JAMA. 2003;289:2685–2694
  30. Gasparini M, Lunati M, Bocchiardo M, Mantica M, Gronda E, Frigerio M, et al. Cardiac resynchronization and implantable cardioverter defibrillator therapy: preliminary results from the InSync implantable cardioverter defibrillator Italian Registry. Pacing Clin Electrophysiol. 2003;26:148–151
  31. Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:1545–1549
  32. Bristow MR, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150
  33. Camm J. Risk stratification for ventricular tachyarrhythmic events by noninvasive methods is possible. Presented at Heart Rhythm Society Sientific Sessions 2004.
  34. Buxton AE. Noninvasive risk stratification for ventricular tachyarrhythmic events. Presented at Heart Rhythm Society Sientific Sessions 2004.
  35. Arya A, Haghjoo M, Sadr-Ameli MA. Risk stratification for arrhythmic death after myocardial infarction: current perspective and future direction. Int J Cardiol; doi:10.1016/j.ijcard.2005.05.011.
  36. Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction and mortality in the 2 years after myocardial infarction. Circulation. 1984;69:250–258
  37. Mukharji J, et al. The MILIS Study Group Risk factors for sudden death after acute myocardial infarction: two-year follow up. Am J Cardiol. 1984;54:31–36
  38. Coromilas J, et al. The MDPIT Research Group Relations among left ventricular dysfunction, ventricular arrhythmias, and mortality after myocardial infarction. Circulation. 1989;80(Suppl. II):48
  39. Bigger JT. Risk stratification after myocardial infarction. Z Kardiol. 1985;74(Suppl. 6):147–157
  40. Yap YG, Duong T, Bland M, Torp-Pederson C, Kober L, Connoly S, et al. Left ventricular ejection fraction in the thrombolytic era remains a powerful predictor of long term but not short-term all cause cardiac and arrhythmicmortality after myocardial infarction—a secondary meta-analysis of 2828 patients. J Am Coll Cardiol. 2001;37(Suppl. A):445A
  41. Zareba W. Noninvasive electrocardiography and outcome in MADIT II patients. In: Presented at the Late-Breaking Clinical Trials session of the North American Society of Pacing and Electrophysiology Annual Scientific Sessions. San Diego, CA, May 8–11. 2002;
  42. Buxton AE, Lee KL, DiCarlo L, Gold MR, Greer GS, Prystowsky EN, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at high risk for sudden death. N Engl J Med. 2000;342:1937–1945
  43. Haigney MC, et al. The MADIT II Investigators QT Interval Variability and Spontaneous Ventricular Tachycardia or Fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol. 2004;44:1481–1487
  44. Bloomfield DM, Steinman RC, Namerow PB, Parides M, Davidenko J, Kaufman ES, et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation. 2004;110:1885–1889
  45. Hohnloser SH, Ikeda T, Bloomfield DM, Dabbous OH, Cohen RJ. T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation. Lancet. 2003;362:125–126
  46. Jackman WM. The future of catheter ablation. Presented at Heart Rhythm Society Sientific Sessions 2004.
  47. Klingenheben T, Zabel M, D’Agostino RB, Cohen RJ, Hohnloser SH. Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure. Lancet. 2000;356:651–652
  48. Ikeda T, Saito H, Tanno K, Shimizu H, Watanabe J, Ohnishi Y, et al. T-wave alternans as a predictor for sudden cardiac death after myocardial infarction. Am J Cardiol. 2002;89:79–82
  49. Gardner PI, Ursell PC, Fenoglio JJ, Wit AL. Electrophysiologic and anatomic basis for fractionated electrograms recorded from healed myocardial infarcts. Circulation. 1985;72:596–611
  50. Denniss AR, Richards DA, Waywood JA, Yung T, Kam CA, Ross DL, et al. Electrophysiological and anatomic differences between canine hearts with inducible ventricular tachycardia and fibrillation associated with chronic myocardial infarction. Circ Res. 1989;64:155–166
  51. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trial. Eur Heart J. 2000;21:2071–2078
  52. Bokhari F, Newman D, Greene M, Korley V, Mangat I, Dorian P. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2004;110:112–116
  53. Salukhe TV, Dimopoulos K, Sutton R, Coats AJ, Piepoli M, Francis DP. Life-years gained from defibrillator implantation markedly nonlinear increase during 3 years of follow-up and its implications. Circulation. 2004;109:1848–1853
  54. Buxton AE. The clinical use of implantable cardioverter defibrillators: where are we now? Where should we go?. Ann Intern Med. 2003;138:512–514
  55. Davis HT, DeCamilla J, Bayer LW, Moss AJ. Survivorship patterns in the posthospital phase of myocardial infarction. Circulation. 1979;60:1252–1258
  56. Bigger JT, et al. The Multicenter Post-Infarction Research Group The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 1984;69:250–258
  57. Mukharji J, Rude RE, Poole WK, Gustafson N, Thomas LJ, Strauss HW, et al. Risk factors for sudden death after acute myocardial infarction: two year follow-up. Am J Cardiol. 1984;54:31–36
  58. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: structure, function, and time-dependence of risk. Circulation. 1992;85(Suppl. I):I-2–I-10
  59. Pires LA, et al. Multicenter Unsustained Tachycardia Trial Investigators Differences in inducibility and prognosis of in-hospital versus out-of-hospital identified nonsustained ventricular tachycardia in patients with coronary artery disease: clinical and trial design implications. J Am Coll Cardiol. 2001;38:1156–1162
  60. Wilber DJ, Zareba W, Hall J, Brown MW, Lin AC, Andrews ML, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation. 2004;109:1082–1084
  61. Seidl K, Senges J. Geographic differences in implantable cardioverter defibrillator usage. J Cardiovasc Electrophysiol. 2002;13:S100–S105

PII: S1443-9506(05)00151-4

doi: 10.1016/j.hlc.2005.08.002

Heart, Lung and Circulation
Volume 15, Issue 1 , Pages 3-11 , February 2006

Article Tools

* Image Usage & Resolution